


5. INTRODUCTION

Background Information

The investigational product is **CuretALL** which is a compound created by Pharma Corporation for the purpose of relieving severe allergic symptoms and can be used by patients suffering from chronic **asthma**. The chemical structure for the compound is as follows:



Chemical Structure of **CuretAll**

Nonclinical Summary

The findings from 12 nonclinical studies (Appendices 2.1 through 2.12) indicate acceptable results for development of **CuretALL** for the indications stated.

Potential Risks and Benefits

There are no known potential risks to humans based on studies to date. There is a potential benefit to patients suffering from chronic **asthma** who are also suffering from allergies.

Route of Administration, Dosage, Dosage Regimen and Treatment Periods

We believe the study will support the premise that a 5mg tablet taken orally upon rising will deliver the most efficacious dosage to study subjects.

Author: borstein	Subject: Redact	Date: 12/3/2007 6:16:45 PM
CuretALL is the trade name for this compound.		
Author: borstein	Subject: Redact	Date: 12/3/2007 6:00:23 PM
Indicated drug is for chronic asthma patients.		
Author: borstein	Subject: Redact	Date: 12/3/2007 6:17:01 PM
Tradename		
Author: borstein	Subject: Redact	Date: 12/3/2007 6:17:10 PM
Tradename		
Author: borstein	Subject: Redact	Date: 12/3/2007 6:17:51 PM
In this instance, the company advises that the drug is for chronic asthma sufferers who also suffer from allergies.		